A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

about

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

Item

http://www.wikidata.org/entity/Q41830195

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

@en

type

Item

label

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

@en

prefLabel

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

@en

P1476

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

@en

P2093

Alain Viari

http://www.w3.org/2001/XMLSchema#string

Anne Vincent-Salomon

http://www.w3.org/2001/XMLSchema#string

Anne-Sophie Sertier

http://www.w3.org/2001/XMLSchema#string

Anthony Ferrari

http://www.w3.org/2001/XMLSchema#string

Daniel Birnbaum

http://www.w3.org/2001/XMLSchema#string

Iris Pauporté

http://www.w3.org/2001/XMLSchema#string

P2860

Mammary stem cells and the differentiation hierarchy: current status and perspectives

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

Novel patterns of genome rearrangement and their association with survival in breast cancer.

Adjuvant trastuzumab in HER2-positive breast cancer.

The origin of breast tumor heterogeneity.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Estimation of rearrangement phylogeny for cancer genomes.

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

P304

e1232186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/23723556.2016.1232186

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Pivot

Pierre Saintigny

P577

2016-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28090578

http://www.w3.org/2001/XMLSchema#string

P932

5160388

http://www.w3.org/2001/XMLSchema#string